Russia has temporarily paused the vaccination of new volunteers in its COVID-19 vaccine trial, as reported This is Money on Thursday.
Staff at eight of the 25 Moscow clinics hosting the trial said the vaccination of new participants was temporarily on hold, and several said they had used up the doses allocated to their clinics, referencing a large influx of volunteers.
Meanwhile, staff at three of the Moscow clinics running the trial said they had run out specifically of the first component of the two-dose vaccine.
"Vaccination is temporarily suspended. We are only injecting the second component," noted one staff member.
However, Alexander Gintsburg, director of the Gamaleya Institute, which developed and is manufacturing the vaccine, said the decision to slow the uptake of new participants was due to a new focus on giving those already vaccinated a second dose.
"Everything is on track. It's simply that the gap between (the number of people inoculated with) the first and second dose is quite significant," Gintsburg said, adding that 20,000 volunteers had received the first dose so far and 9000 the second.